Clinical Trial Update: Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers [Phase 1]

View source ↗

Summary

The document reports on a Phase 1 study of REGN3767 alone or with REGN2810 in patients with advanced cancers, which has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• REGN2810
• REGN3767

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Malignancies | Phase 1 | Status: COMPLETED